Craig Adeyanju

InvestorPlace Contributor

Craig Adeyanju enjoys to unearth awesome growth and value stocks and educate investors about the companies behind them. He believes that the best companies to invest in are those that genuinely solve a problem.

His work has appeared on sites like TheStreet, The Motley Fool, Benzinga among others.

Recent Articles

Amazon Prime Day: Walmart (WMT) Won’t Win by Copycatting

By Craig Adeyanju, InvestorPlace Contributor Jul 15, 2015

While Walmart (WMT) wants to show that it cares more about consumers, it's still going to be the loser in the Amazon Prime Day retail war.

Why Airline Stocks Should Be on Your Income Radar

By Craig Adeyanju, InvestorPlace Contributor Jun 15, 2015

Recent dividend increases by airline stocks Southwest (LUV) and Delta (DAL) will become more norm than exception as airlines continue to reap the benefits of a less-crowded field.

Did Alexion Jump the Shark With Its Synageva Bid? (ALXN, GEVA)

By Craig Adeyanju, InvestorPlace Contributor May 15, 2015

While ALXN seems to have overpaid for GEVA on the surface. However, investors can expect to see the benefits over the long-term.

Should You Buy Chipotle Stock? 3 Pros, 3 Cons (CMG)

By Craig Adeyanju, InvestorPlace Contributor May 5, 2015

Chipotle stock has shed about 10% since the company's first-quarter report. However, with significant growth opportunities on the horizon, is this a buying point for CMG?

Biogen (BIIB): Why Aducanumab Excitement Might Be Overblown

By Craig Adeyanju, InvestorPlace Contributor Mar 30, 2015

Biogen Inc (BIIB) recently shot up after reporting positive results from aducanumab's phase 1b study. However, there are some important takeaways from the report that many seem to be missing.